Literature DB >> 12477733

Regulation of isoprenoid/cholesterol biosynthesis in cells from mevalonate kinase-deficient patients.

Sander M Houten1, Marit S Schneiders, Ronald J A Wanders, Hans R Waterham.   

Abstract

Mevalonic aciduria (MA) and hyper-IgD and periodic fever syndrome (HIDS) are two inherited disorders both caused by depressed mevalonate kinase (MK) activity. MK is the first enzyme to follow the highly regulated 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase (HMGR), which catalyzes the rate-limiting step in the isoprenoid/cholesterol biosynthesis pathway. In fibroblasts of MA patients, but not of HIDS patients, HMGR activity is elevated under normal growth conditions. This activity is down-regulated when cells are supplemented with the isoprenoid precursors geraniol, farnesol, and geranylgeraniol, and a mixture of 25-hydroxycholesterol and cholesterol. This indicates that the regulation of the pathway in these cells is not disturbed. The elevated HMGR activity is probably due to a shortage of non-sterol isoprenoid end products, as indicated by normal HMGR mRNA levels in MA fibroblasts. Furthermore, the HMGR activity in MA cells was more sensitive to geranylgeraniol suppression and less sensitive to sterol suppression than the HMGR activity in low density lipoprotein receptor-deficient cells. HMGR activity in MA cells was down-regulated also by addition of its product mevalonate to the culture medium. Thus, it appears that the elevation of mevalonate levels, which are high in MA patients and moderate in HIDS patients, allows the cells to compensate for the depressed MK activity. Indeed, the isoprenylation of Ras and RhoA protein appeared normal in HIDS and MA fibroblasts under normal conditions but showed increased sensitivity toward inhibition of HMGR by simvastatin. Our results indicate that MK-deficient cells maintain the flux through the isoprenoid/cholesterol biosynthesis pathway by elevating intracellular mevalonate levels.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12477733     DOI: 10.1074/jbc.M206564200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Geranylgeraniol suppresses the viability of human DU145 prostate carcinoma cells and the level of HMG CoA reductase.

Authors:  Nicolle V Fernandes; Hoda Yeganehjoo; Rajasekhar Katuru; Russell A DeBose-Boyd; Lindsey L Morris; Renee Michon; Zhi-Ling Yu; Huanbiao Mo
Journal:  Exp Biol Med (Maywood)       Date:  2013-09-04

2.  Squalene epoxidase (SQLE) promotes the growth and migration of the hepatocellular carcinoma cells.

Authors:  Zhenghui Sui; Jiahua Zhou; Zhangjun Cheng; Penhua Lu
Journal:  Tumour Biol       Date:  2015-03-19

3.  Compromized geranylgeranylation of RhoA and Rac1 in mevalonate kinase deficiency.

Authors:  L Henneman; M S Schneiders; M Turkenburg; H R Waterham
Journal:  J Inherit Metab Dis       Date:  2010-09-03       Impact factor: 4.982

Review 4.  Isoprenoids: remarkable diversity of form and function.

Authors:  Sarah A Holstein; Raymond J Hohl
Journal:  Lipids       Date:  2004-04       Impact factor: 1.880

Review 5.  Inborn errors of metabolism underlying primary immunodeficiencies.

Authors:  Nima Parvaneh; Pierre Quartier; Parastoo Rostami; Jean-Laurent Casanova; Pascale de Lonlay
Journal:  J Clin Immunol       Date:  2014-08-01       Impact factor: 8.317

6.  Unprenylated RhoA contributes to IL-1β hypersecretion in mevalonate kinase deficiency model through stimulation of Rac1 activity.

Authors:  Robert van der Burgh; Kalliopi Pervolaraki; Marjolein Turkenburg; Hans R Waterham; Joost Frenkel; Marianne Boes
Journal:  J Biol Chem       Date:  2014-08-08       Impact factor: 5.157

7.  Consequences of blunting the mevalonate pathway in cancer identified by a pluri-omics approach.

Authors:  Sophie Goulitquer; Mikaël Croyal; Julie Lalande; Anne-Lise Royer; Yann Guitton; Danielle Arzur; Stéphanie Durand; Catherine Le Jossic-Corcos; Alain Bouchereau; Philippe Potin; Serge Akoka; Jean-Philippe Antignac; Michel Krempf; Véronique Ferchaud-Roucher; Patrick Giraudeau; Laurent Corcos
Journal:  Cell Death Dis       Date:  2018-07-03       Impact factor: 8.469

8.  Inhibition of Orbivirus Replication by Fluvastatin and Identification of the Key Elements of the Mevalonate Pathway Involved.

Authors:  Fauziah Mohd Jaafar; Baptiste Monsion; Mourad Belhouchet; Peter P C Mertens; Houssam Attoui
Journal:  Viruses       Date:  2021-07-23       Impact factor: 5.048

9.  Reduced serpinB9-mediated caspase-1 inhibition can contribute to autoinflammatory disease.

Authors:  Robert van der Burgh; Jan Meeldijk; Lieneke Jongeneel; Joost Frenkel; Niels Bovenschen; Mariëlle van Gijn; Marianne Boes
Journal:  Oncotarget       Date:  2016-04-12

10.  Mevalonate kinase deficiency leads to decreased prenylation of Rab GTPases.

Authors:  Julie Jurczyluk; Marcia A Munoz; Oliver P Skinner; Ryan C Chai; Naveid Ali; Umaimainthan Palendira; Julian Mw Quinn; Alexandra Preston; Stuart G Tangye; Andrew J Brown; Elizabeth Argent; John B Ziegler; Sam Mehr; Michael J Rogers
Journal:  Immunol Cell Biol       Date:  2016-07-05       Impact factor: 5.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.